Cancer Diagnostics Market Size, Share, By Method (Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Fluorescent Assay (ELFA), Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunohistochemistry, Microarray, Imaging, Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), Positron Emission Tomography (PET), Ultrasound, Mammography, Biopsy, and Others), By Disease Indication (Breast cancer, Colorectal cancer, Cervical cancer, Lung cancer, Prostate cancer, Skin cancer, Blood cancer, Kidney cancer, Liver cancer, Pancreatic cancer, Ovarian cancer, and Others), and By Region - Trends, Analysis, and Forecast till 2034

Cancer Diagnostics Market Size was valued at USD 3.0 billion in 2024 and is projected to grow at a CAGR of 6.2%to reach USD 5.8 billion by 2034.

Cancer diagnostics and its market have economically grown over the decades. One of the leading causes of death globally is cancer, and the disease's incidence is frighteningly rising. In order to lower the incidence level, medical professionals are focusing on creating effective treatment and diagnostic strategies. Treatment regimen success rates are increased with early discovery. As a result, through various awareness campaigns, medical facilities and businesses are encouraging routine exams.

Increment in the incidence and prevalence of various cancers, including breast and lung cancer, could propel the market during the anticipated time frame. Additionally, a surge in technological advancements enabling better imaging of hazardous cells, equipment developments for identifying the type of cancer, and an improvement in the precision of the outcome might help the market gain momentum throughout the course of the projection period.

Key Drivers Cancer Diagnostics Market Drivers:   

Growing incidence of cancer

• The overall death toll is rising in tandem with the world's population growth. From roughly 46 million in 1990 to 56 million in 2019, there have been more fatalities.
  Naturally, this implies that there are now more people who have not passed away from cancer. Most cancer deaths occur in elderly adults. According to estimates, 1 in 100 (or 1% yearly) of those 70 years of age or over lost their lives to cancer in 2019. However, the cancer death rate was over 40 times lower among those under 50.
• It makes sense that a large proportion of cancer deaths would occur in older populations as opposed to younger ones. The world is aging quickly while health is rising and fertility rates are declining. It is considered as driving factor for the market.

Rising Expenditure of Healthcare

• These cost estimates account for oral prescription medication and medical services related to cancer. The highest national medical service expenses were associated with non-Hodgkin lymphomas and malignancies of the prostate, lung, colon, and female breast.
  Medical services care costs, which comprise Medicare payments as well as patient obligations for all billed medical services, such as hospitalizations, outpatient hospital services, physician/supplier services, infusion or injectable drug, durable medical equipment, and hospice care, were estimated from Medicare Parts A and B claims.

Development of small-scale clinics

• The large number of clinics have adopted tools for cancer detection like MRI, CT-scans and other. This has led to growth in healthcare sector and global economy. It is also a milestone for healthcare services.

Restraints:

High Implementation Costs

• Implementing Cancer Diagnostics Market can require significant upfront investment, including the cost of the software itself, customization, and integration with existing systems. This can be a barrier for smaller hospitals with limited budgets.
• In addition to the initial outlay, there are continuing costs for user training, software updates, and maintenance. Some businesses may find it difficult to continue their cancer diagnostics efforts due to these escalating expenditures.

Lack of Standardization

• The regulatory landscape for cancer diagnostics is constantly evolving, with new guidelines and requirements emerging regularly. Keeping up with these changes and adjusting reporting practices accordingly can be a daunting task for companies.
• While there are several cancer therapeutics and diagnostics frameworks, there is no universal standard, which can create confusion and inconsistency in reporting practices. Companies may find it challenging to choose the right framework and ensure their reporting meets multiple stakeholders' requirements.

Cancer Diagnostics Market is segmented based on based on by Method, By Disease Indication and Region.

Methods Insight

• Enzyme-Linked Fluorescent Assay (ELFA)- Like ELISA, but with the potential for improved sensitivity and specificity because it detects and quantifies compounds using fluorescent markers rather than enzymes.
• Polymerase Chain Reaction (PCR)- a molecular biology method that amplifies DNA sequences to enable the detection and analysis of minute amounts of DNA, which is essential for forensics, diagnostics, and genetic research.
• Next Generation Sequencing (NGS) - a high-throughput technique that makes it possible to quickly sequence DNA or RNA, enabling thorough research of transcriptomes, genomes, and epigenomes, and advancing fields such as evolutionary biology and personalized medicine.
• Immunohistochemistry- It a technique that uses antibodies integrated with dyes or enzymes to see particular proteins in tissue samples, aiding in the understanding of tissue morphology and the diagnosis of illnesses like cancer.
• Microarray- a device that offers insights into genetic variants and disease causes by immobilizing probes on a solid surface and allowing them to hybridize with DNA or RNA samples in order to evaluate gene expression or discover mutations.
• Imaging Techniques -such as MRI, CT scans, PET scans, and ultrasound used to visualize internal structures of the body for diagnosis and monitoring of diseases.
• Magnetic Resonance Imaging (MRI)- helps with the detection of diseases affecting soft tissues and organs by producing precise images of organs and tissues using radio waves and high magnetic fields.
• Computed Tomography (CT scan)- It Combines X-ray images taken from different angles to create cross-sectional images of bones, blood vessels, and soft tissues, helpful in diagnosing injuries, tumours, and infections.
• Positron Emission Tomography (PET)-Utilizes radioactive tracers to detect metabolic changes in tissues, useful in assessing organ function and detecting diseases like cancer. It has been a major invention for cancer diagnostics.
• Ultrasound- Uses high-frequency sound waves to produce images of organs and structures inside the body, non-invasively, commonly used in obstetrics and cardiology.
• Mammography- X-ray imaging of breast tissue used primarily for screening and diagnosing breast cancer, crucial in early detection and treatment planning.
• Biopsy- This involves the removal of a small sample of tissue for microscopic examination, aiding in diagnosing diseases such as cancer and determining appropriate treatment.

Disease Indication Insights

• Breast cancer- It is a type of cancer that begins in the breast cells and frequently manifests as a lump that is felt or shown on a mammography. It is the most prevalent cancer in women worldwide, and if left untreated, it can spread to neighbouring lymph nodes and other body areas.
• Colorectal cancer- This cancer typically starts as precancerous polyps in the intestinal lining and affects the colon or rectum. Changes in bowel patterns, blood in the stool, and discomfort in the abdomen are some of the symptoms. Early detection through screening maximizes the effectiveness of treatment.
• Cervical Cancer- Cancer that begins in the cervix, or lower section of the uterus, is known as cervical cancer. Certain strains of the human papillomavirus (HPV) are the cause, and HPV vaccination can prevent it.
• Lung Cancer- This lung cancer is commonly linked to smoking, but it can also strike non-smokers as a result of exposure to asbestos and radon in the environment or second-hand smoke. Breathing difficulties, chest pain, and a chronic cough are some of the symptoms.
• Prostate Cancer- It a type of cancer that strikes men's prostate glands. It often grows slowly and may not show any symptoms at first. Early detection can be achieved with digital rectal exams and PSA blood test screening. Active surveillance, surgery, radiation, and hormone therapy are among the available treatment options.
• Skin Cancer-UV radiation from the sun or tanning beds is the main cause of skin cancer, which includes non-melanoma varieties including basal cell carcinoma and squamous cell carcinoma as well as melanoma, which is the deadliest type. Prevention and treatment depend heavily on early detection and sun protection.
• Blood Cancer- It affects the lymphatic system, bone marrow, and blood; it is also referred to as hematologic cancer. There are three types: myeloma (cancer of plasma cells), lymphoma (cancer of the lymphatic system), and leukaemia (cancer of the blood and bone marrow). Stem cell transplants, radiotherapy, and chemotherapy are possible treatment options.
• Kidney Cancer- This malignancy, which starts in the kidneys, frequently shows no signs at first. Urine containing blood, lower back or side pain, and inexplicable weight loss are possible symptoms. Treatment options include immunotherapy, targeted therapy, and surgery, depending on the stage.
• Liver Cancer - Hepatocellular carcinoma is the most frequent type of malignant malignancy, which begins in the liver cells. It is frequently associated with long-term liver conditions such alcoholism, cirrhosis, and infections with hepatitis B or C. Swelling, soreness in the abdomen, and jaundice are among the symptoms. Among the available treatment options are targeted therapy, ablation, and surgery.
• Pancreatic Cancer- This cancer, which starts in the pancreas, is frequently discovered later since its initial symptoms are hazy.  Family history, obesity, and smoking are risk factors. Depending on the stage, treatment options include radiation therapy, chemotherapy, and surgery.
• Ovarian Cancer- This cancer, which develops in the ovaries, is challenging to identify in its early stages because symptoms including bloating, stomach pain, and changes in bowel habits are frequently misdiagnosed as less serious illnesses. It can be detected by screening with pelvic exams and imaging, and treatment options include chemotherapy and surgery.

 Regional Insights:

On region the Cancer Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America particularly the United States and Canada, is a significant market for Cancer Diagnostics Market due to strong regulatory frameworks and increasing investor demand for transparency in sustainability practices as well greater consideration for public health domain drives the market upwards.
• Asia Pacific region is rapidly growing in the Cancer Diagnostics Market due to increasing regulatory developments, investor interest, and corporate sustainability efforts. Countries like Japan, South Korea, and Australia are enhancing their cancer therapeutics and diagnostics requirements. China is also beginning to emphasize cancer diagnostics as part of its broader economic reforms.
• Europe is expected to dominate the target market growth and this region is also considered a leader in the Cancer Diagnostics Market, driven by rigorous regulations and a strong cultural emphasis on sustainability and healthcare management practices.
• Latin America is emerging as a promising market for cancer diagnostics, driven by increasing awareness and regulatory initiatives. There is a growing awareness of cancer and healthcare among businesses and investors in Latin America. This has led to increased adoption of cancer diagnostics practices.
• Middle East & Africa region is a growing interest from both regional and international investors in global cancer therapeutics market, driving companies to adopt cancer diagnostic tools to enhance transparency and attract investment.  

Cancer Diagnostics Market Report Scope:

Attribute	Details
Market Size 2024	USD 3.0 Billion
Projected Market Size 2034	USD 5.8 Billion
CAGR Growth Rate	6.2%
Base year for estimation	2023
Forecast period	2024-2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Methods- Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Fluorescent Assay (ELFA), Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunohistochemistry, Microarray, Imaging, Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), Positron Emission Tomography (PET), Ultrasound, Mammography, Biopsy, and Others. By Disease Indication – Breast cancer, Colorectal cancer, Cervical cancer, Lung cancer, Prostate cancer, Skin cancer, Blood cancer, Kidney cancer, Liver cancer, Pancreatic cancer, Ovarian cancer, and Others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Cancer Diagnostics Market report based on Methods, Disease indication Region:

By Method:

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Enzyme-Linked Fluorescent Assay (ELFA)
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Immunohistochemistry, Microarray
• Imaging
• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT scan)
• Positron Emission Tomography (PET)
• Ultrasound,
• Mammography
• Biopsy
• Others

By Disease Indication:

• Breast cancer
• Colorectal cancer
• Cervical cancer
• Lung cancer
• Prostate cancer
• Skin cancer
• Blood cancer
• Kidney cancer
• Liver cancer
• Pancreatic cancer
• Ovarian cancer
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Cancer Diagnostics Market includes, Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company, Agilent Technologies, Inc., Roche Diagnostics GmbH, QIAGEN N.V., Illumina, Inc., Eli Lilly and Co., and Philips Healthcare Informatics, Inc.

• In In December 2022, India-based startup PredOmix launched a one-of-its-kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with a 98% accuracy. Even as detecting cancer early remains key, a Gurugram-based startup PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women, with 98 per cent accuracy. The company's OncoVeryx-F is a patented Methods that combines metabolomics (study of small molecules) and Artificial Intelligence (AI) to identify metabolite signatures of multiple cancers.
• In June 2022, in a The BenchMark series, which completely automated previously manual operations, one slide at a time, revolutionized cancer diagnosis. The new BenchMark ULTRA PLUS system carries on this legacy. Thanks to improved productivity and quality control processes, as well as simpler software, lab staff will be able to manage their tasks more effectively. These improvements may facilitate the faster distribution of test results to patients awaiting a diagnosis. single test.

• Abbott Laboratories*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Thermo Fisher Scientific Inc.,
• Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Roche Diagnostics GmbH
• QIAGEN N.V.
• Illumina Inc.,
• Eli Lilly and Co
• Philips Healthcare Informatics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Methods
  • Market Snippet, By Disease Indication
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Enzyme-Linked Immunosorbent Assay (ELISA)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Enzyme-Linked Fluorescent Assay (ELFA)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Polymerase Chain Reaction (PCR)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

• Next Generation Sequencing (NGS)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Immunohistochemistry
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Micro array
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Imaging
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• MRI
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Computed Tomography (CT scan)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Positron Emission Tomography (PET)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Ultrasound
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Mammography
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Biopsy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
•  Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Disease Indication, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Breast cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Colorectal Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Cervical Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Lung Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Prostate cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Skin Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Blood Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Kidney Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Pancreatic Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Ovarian Cancer
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Methods, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Disease Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Methods, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Disease Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (US$ Bn), By Methods, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Disease Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (US$ Bn), By Methods, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Disease Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (US$ Bn), By Methods, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Disease Indication, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Abbott Laboratories
• Thermo Fisher Scientific Inc.,
• Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Roche Diagnostics GmbH
• QIAGEN N.V.
• Illumina Inc.,
• Eli Lilly and Co
• Philips Healthcare Informatics, Inc.

The Last Word

• Future Impact
• About Us
• Contact